Is Supha Pharmachem Ltd (539561) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Supha Pharmachem Ltd is a below average quality company .

Is Supha Pharmachem Ltd (539561) undervalued or overvalued?

The key valuation ratios of Supha Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Supha Pharmachem Ltd (539561) share price return in the past 10 years?

Data is not available for this company

Is Supha Pharmachem Ltd (539561) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Supha Pharmachem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Supha Pharmachem Ltd (539561)?

Company share prices are keep on changing according to the market conditions. The current trading price of Supha Pharmachem Ltd (539561) on 13-Apr-2026 11:17:00 at 11:17 is 0.39.

What is the P/E ratio of Supha Pharmachem?

The latest standalone P/E ratio of Supha Pharmachem as of 13-Apr-2026 is 0.00.

What is the P/B ratio of Supha Pharmachem Ltd (539561)?

The latest standalone P/B ratio of Supha Pharmachem Ltd (539561) as of 13-Apr-2026 is 0.37.

What is the 52-week high and low of Supha Pharmachem Ltd (539561)?

The 52-week high of Supha Pharmachem Ltd (539561) is Rs. 1.94 and the 52-week low is Rs. 0.32.

Supha Pharmachem Ltd (539561) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Supha Pharmachem Ltd (539561)
Brand: Supha Pharmachem

Supha Pharmachem Ltd (539561) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Key Metrics

Market Cap

₹34 Cr.

P/E Ratio

0.00

Price to Book (P/B)

0.37

Price to Sales (P/S)

0.23

EV/EBITDA

1159.22

Return on Capital Employed (ROCE)

1.76%

Current Price

₹0.4

Return on Equity (ROE)

3.55%

Return on Assets (ROA)

0.09%

Operating Profit Margin

0.2%

Net Profit Margin

0.69%

Gross Profit Margin

1.7%

Book Value per Share

₹1

Sales Growth (YoY)

-94.49%

Sales Growth (3 Years)

-23.9%

Operating Profit Growth (1 Year)

-98.42%

Operating Profit Growth (3 Years)

-33.3%

Net Profit Growth (1 Year)

-95.33%

52-Week Low / High

₹0 / 2

Net Profit Growth (3 Years)

12.44%

Dividend Yield

0.00%

Promoter Holding

1.13%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1

Supha Pharmachem Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.

Q.1 Gross Profit margin of Supha Pharmachem Ltd?

Supha Pharmachem Ltd Gross profit margin which is the profit after deduction of direct costs, is 1.7% for FY-2025 , which is above its 5 year median of 0% , indicating increasing margins.

Q.1 Promoter shareholding and pledge status of Supha Pharmachem Ltd?

Promoters hold 1.13% of the Supha Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Supha Pharmachem Ltd vs industry peers?

Supha Pharmachem Ltd revenue CAGR is 138.39% , compared to the industry median CAGR of 17.75% , indicating faster growth and gaining its market share.

Q.1 Stock return of Supha Pharmachem Ltd over the last decade?

Over the last 9 years, the stock has delivered a CAGR of 0% based on the current price.

Q.1 Is Supha Pharmachem Ltd a good quality company?

Supha Pharmachem Ltd is a quality company, based on a 10 year financial track record .

DeciZen - make an informed investing decision on Supha Pharmachem

Based on:

Data

M-Cap below 100cr DeciZen not available

Supha Pharmachem stock performance

Key Ratios

Is Supha Pharmachem Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	0.7%	0.1%	0.6%	0.6%	11.2%	7.4%	18.2%	102.5%	99.5%	1.8%	-
Value Creation Index ⓘ	-1.0	-1.0	-1.0	-1.0	-0.2	-0.5	0.3	6.3	6.1	-0.9	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	3.9	1.3	0.4	0.2	2.9	90	505	510	4,042	223	147
Sales YoY Gr.	-	-66.2%	-73.7%	-54.3%	1,706.3%	3,015.2%	460.7%	1%	692.7%	-94.5%	-
Adj EPS ⓘ	0	0	0	0	0	0	0	0.1	0.3	-0.1	-0
YoY Gr.	-	NA	NA	NA	NA	NA	100%	300%	287.5%	-132.3%	-
BVPS (₹) ⓘ	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.7	0.8	1
Adj Net Profit ⓘ	0	0	0	0	0.3	0.5	1.1	4.9	18	-5.9	-2
Cash Flow from Ops. ⓘ	-1.4	0.1	-0.2	-0.1	-0.2	-10.2	11.3	20.5	-74.2	-1,079	-
Debt/CF from Ops. ⓘ	-0	0	0	-1.1	-1.8	-1	0	0	-0.8	-1.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	56.6%	138.4%	-23.9%	-94.5%
Adj EPS ⓘ	NA	NA	-271%	-132.3%
BVPSⓘ	35.1%	65.7%	102.7%	1.4%
Share Price	-	8.5%	-60.8%	-74.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	0.3	0.1	0.5	0.2	8.4	13.3	24.5	63.4	67.7	-13.8	-2.3
Op. Profit Mgn % ⓘ	-7.6	-7.4	0.2	-43.2	13.4	0.8	0.4	1.4	0.9	0.2	-9.4
Net Profit Mgn % ⓘ	0.2	0.3	3.9	3.9	9.4	0.5	0.2	1	0.5	-2.7	-1.2
Debt to Equity ⓘ	0	0	0	0	0.1	2.7	0	0	1.3	26.4	12
Working Cap Days ⓘ	415	1,050	3,243	6,366	351	82	94	485	139	2,858	4,398
Cash Conv. Cycle ⓘ	325	801	2,189	2,045	110	10	17	27	21	1,038	3,071

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	-0	0
TTM Sales (₹ Cr.)	147	405
BVPS (₹) ⓘ	1	1.2
Reserves (₹ Cr.) ⓘ	3	17
P/BV ⓘ	0.37	0.32
PE ⓘ	0.00	15.74

From the Market
52 Week Low / High (₹)	0.32 / 1.94
All Time Low / High (₹)	0.07 / 31.35
Market Cap (₹ Cr.)	33.5
Equity (₹ Cr.)	88.2
Face Value (₹)	1
Industry PE ⓘ	24.2

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Supha Pharmachem - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	3.93	1.33	0.35	0.16	2.89	90.03	504.79	509.84	4,041.71	222.50
Operating Expenses ⓘ +	4.23	1.43	0.35	0.23	2.50	89.31	502.98	502.67	4,007.51	221.96
Manufacturing Costs	0.59	0.79	0.02	0.01	0.13	0.21	1.74	1.74	1.01	1.42
Material Costs	3.39	0.46	0.14	0.05	1.67	87.74	498.47	493.86	4,001.38	216.11
Employee Cost	0.05	0.04	0.13	0.04	0.18	0.19	0.21	0.55	0.40	0.41
Other Costs ⓘ	0.21	0.14	0.06	0.13	0.52	1.17	2.56	6.52	4.72	4.02
Operating Profit ⓘ	-0.30	-0.10	0	-0.07	0.39	0.72	1.82	7.17	34.19	0.54
Operating Profit Margin (%)	-7.6%	-7.4%	0.2%	-43.2%	13.4%	0.8%	0.4%	1.4%	0.8%	0.2%
Other Income ⓘ +	0.33	0.10	0.02	0.09	0.01	0.01	0.01	0.83	21.10	10.80
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.01	0	0	0	0.01	0.02	0.23	0.45	4.78	7.64
Depreciation ⓘ	0.01	0	0	0	0.01	0.06	0.07	0.15	0.06	0.04
Profit Before Tax ⓘ	0.01	0	0.02	0.02	0.38	0.65	1.53	7.40	50.45	3.66
Tax ⓘ	0	0	0	0.01	0.10	0.17	0.45	1.97	17.72	2.13
Profit After Tax	0.01	0	0.01	0.01	0.28	0.48	1.08	5.43	32.73	1.53
PAT Margin (%)	0.3%	0.3%	3.9%	5.0%	9.6%	0.5%	0.2%	1.1%	0.8%	0.7%
Adjusted EPS (₹)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	3.04	3.04	3.07	3.08	3.35	3.86	4.94	10.36	42.96	43.30
Share Capital ⓘ	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60	10.08	40.32
Reserves ⓘ	-0.56	-0.56	-0.53	-0.52	-0.25	0.26	1.34	6.76	32.88	2.98
Debt +	0	0	0	0.08	0.36	10.50	0	0	57.70	1,141.39
Long Term Debt	0	0	0	0.08	0.36	10.50	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	57.70	1,141.39
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	1.37	0	0	0.35	0.39	23.77	124.56	84.22	712.29	320.98
Others Liabilities ⓘ	0.16	0.25	0.06	0.02	0.16	0.40	94.26	1,059.63	1,134.95	33.94
Total Liabilities ⓘ	4.57	3.29	3.13	3.53	4.27	38.53	223.76	1,154.22	1,947.90	1,539.61
Fixed Assets
Net Fixed Assets ⓘ +	0.02	0.01	0.01	0	0.23	0.21	0.19	0.08	0.05	0.01
Gross Block	0.21	0.21	0.21	0	0.24	0.29	0.34	0.20	0.22	0.22
Accumulated Depreciation	0.19	0.19	0.20	0	0.01	0.08	0.15	0.12	0.18	0.22
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0.07
Inventories	0.83	0	0	0.20	0.70	3.11	83.87	7.32	133.23	269.38
Trade Receivables	2.85	2.17	2.03	0.14	1.50	23.68	64	172.37	920.60	590.92
Cash Equivalents	0.01	0.16	0.02	1.08	0.93	0.81	1.44	21.86	1.52	1.36
Others Assets ⓘ	0.86	0.95	1.07	2.11	0.91	10.72	74.27	952.59	892.49	677.88
Total Assets ⓘ	4.57	3.29	3.13	3.53	4.27	38.53	223.76	1,154.22	1,947.90	1,539.61

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-1.36	0.07	-0.16	-0.07	-0.20	-10.21	11.28	20.50	-74.16	-1,078.63
PBT ⓘ	0.01	0	0.02	0.01	0.38	0.65	1.53	7.40	50.45	3.66
Adjustment ⓘ	-0.05	-0.09	0	-0.09	0.01	0.06	0.18	0.19	3.84	5.20
Changes in Working Capital ⓘ	-1.32	0.15	-0.17	0	-0.59	-10.89	10.03	14.89	-110.64	-1087
Tax Paid ⓘ	-0	-0	-0	0.01	0	-0.04	-0.45	-1.98	-17.81	-0.49
Cash Flow From Investing Activity ⓘ +	1.48	0.09	0.02	1.06	-0.24	-0.04	-0.05	-0.04	0.09	0.06
Capex	1.41	0	0	0.02	-0.24	-0.04	-0.05	-0.04	0	0
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.07	0.09	0.02	1.04	0	0	0	0	0.09	0.06
Cash Flow From Financing Activity ⓘ +	-0.11	-0	-0	0.08	0.29	10.14	-10.61	-0.04	53.74	1,078.40
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0.10	-0	0	0	0.29	10.14	-10.50	0	0	0
Interest Paid ⓘ	-0.01	-0	-0	0	0	0	-0.11	-0.04	-3.87	-5.29
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0	0	0	0.08	0	0	0	0	57.61	1,083.69
Net Cash Flow ⓘ	0	0.15	-0.14	1.06	-0.15	-0.11	0.62	20.42	-20.33	-0.16

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0.36	0.11	0.45	0.26	8.62	13.33	24.51	70.92	122.76	3.55
ROCE (%)	0.66	0.14	0.55	0.62	11.16	7.39	18.16	102.54	99.51	1.76
Asset Turnover Ratio	0.76	0.34	0.11	0.05	0.74	4.21	3.85	0.74	2.61	0.13
PAT to CFO Conversion(x)	-136	N/A	-16	-7	-0.71	-21.27	10.44	3.78	-2.27	-704.99
Working Capital Days
Receivable Days	224	688	2,189	2,487	103	51	32	85	49	1,240
Inventory Days	100	0	0	470	57	8	31	33	6	330
Payable Days	0	0	0	1,426	81	50	54	77	36	873

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Supha Pharmachem Ltd FAQs

The current trading price of Supha Pharmachem on 13-Apr-2026 11:17 is ₹0.39.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2026 the market cap of Supha Pharmachem stood at ₹33.52 Cr

The latest P/E ratio of Supha Pharmachem as of 12-Apr-2026 is 0.00.

The latest P/B ratio of Supha Pharmachem as of 12-Apr-2026 is 0.37.

The 52-week high of Supha Pharmachem is ₹1.94 and the 52-week low is ₹0.32.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Supha Pharmachem is ₹147 ( Cr.) .

About Supha Pharmachem Ltd

Remedium Lifecare Ltd. (formerly known as Roxy Exports Limited) is a BSE listed company. The company has made a paradigm shift by entering into the manufacturing of intermediates and APIs and be reckoned as a leading contract manufacturer and as a brand owner of advanced intermediates & APIs. The strategic acquisition of the state-of-the-art manufacturing facilities in Hyderabad, was a timely move to forward integrate and diversify into the pharma & healthcare arena. A massive facility with 2 dedicated manufacturing blocks is now ready for large scale manufacture.

The company is engaged into the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Amino isophthalic Acid, Tellurium (IV) Oxide, Grignard Reagent, lodine, Selenium Metal Powder, Trimethyl Sulfoxonium lodide (TMSI).

Business area of the company

The company is pharmaceutical company aligned across two business verticals viz. Products and Services. Its Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both Domestic and International markets including the regulated markets.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Supha Pharmachem Ltd (539561) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Supha Pharmachem Share Price